Harrow, Inc. (NASDAQ:HROW) Stock Has Average Target Price of $66.17

Harrow, Inc. (NASDAQ:HROW) has been assigned an average recommendation of “Moderate Buy” from the ten research firms that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $66.17.

HROW has been the subject of several recent analyst reports. Wall Street Zen upgraded shares of Harrow from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Zacks Research raised shares of Harrow from a “strong sell” rating to a “hold” rating in a report on Wednesday, September 9th. BTIG Research reiterated a “buy” rating and set a $63.00 price target on shares of Harrow in a research report on Tuesday, August 11th. Weiss Ratings reissued a “sell (e+)” rating on shares of Harrow in a research note on Monday, July 20th. Finally, Leerink Partners assumed coverage on Harrow in a report on Wednesday, September 9th. They issued an “outperform” rating and a $45.00 price target on the stock.

Insider Transactions at Harrow

In other Harrow news, insider Amir Shojaei sold 11,250 shares of the business’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $40.00, for a total transaction of $450,000.00. Following the sale, the insider directly owned 11,250 shares in the company, valued at approximately $450,000. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 12.80% of the company’s stock.

Institutional Trading of Harrow

Large investors have recently bought and sold shares of the company. BlackRock Inc. acquired a new position in Harrow during the second quarter worth about $116,373,000. Bamco Inc. NY acquired a new stake in shares of Harrow in the second quarter valued at approximately $34,373,000. Jupiter Topco LLC purchased a new position in shares of Harrow during the 2nd quarter worth approximately $24,596,000. Rice Hall James & Associates LLC purchased a new position in shares of Harrow during the 2nd quarter worth approximately $16,459,000. Finally, Dimensional Fund Advisors LP raised its position in shares of Harrow by 56.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 579,520 shares of the company’s stock worth $20,428,000 after purchasing an additional 208,972 shares during the last quarter. Institutional investors and hedge funds own 72.76% of the company’s stock.

Harrow Stock Performance

NASDAQ HROW opened at $30.48 on Wednesday. The stock has a market capitalization of $1.14 billion, a price-to-earnings ratio of -30.48 and a beta of 0.19. The business’s 50 day moving average is $37.12 and its two-hundred day moving average is $37.67. Harrow has a 12-month low of $28.54 and a 12-month high of $54.85. The company has a current ratio of 2.24, a quick ratio of 2.08 and a debt-to-equity ratio of 19.70.

Harrow (NASDAQ:HROW) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.28). Harrow had a negative return on equity of 38.00% and a negative net margin of 13.51%.The business had revenue of $70.66 million during the quarter, compared to analysts’ expectations of $70.35 million.

Harrow Company Profile

Harrow, Inc is an ophthalmic pharmaceutical company focused on developing, acquiring, and commercializing prescription products for the treatment of eye conditions. Its portfolio is designed to serve ophthalmologists, optometrists, ambulatory surgery centers, and other eye-care providers across areas including dry eye disease, ocular inflammation, infection, and surgical care.

The company’s products include VEVYE, a cyclosporine ophthalmic emulsion for the treatment of signs and symptoms of dry eye disease, and IHEEZO, an ophthalmic anesthetic used in certain ocular procedures.